NCT01162486 - Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

February 28, 2011

Study Completion Date

March 31, 2011

Conditions

TuberculosisTuberculosis, Pulmonary

Interventions

DRUG

Rifampin & midazolam

rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

DRUG

rifapentine & midazolam

rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

DRUG

rifapentine & midazolam

rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

DRUG

rifapentine & midazolam

rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

DRUG

rifapentine and midazolam

rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

DRUG

rifapentine and midazolam

rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15

Trial Locations (1)

Johns Hopkins University, Baltimore